Cooper Companies (NASDAQ:COO) Rating Lowered to “Neutral” at Rothschild & Co Redburn

Cooper Companies (NASDAQ:COO) was downgraded by Rothschild & Co Redburn from a “buy” rating to a “neutral” rating in a research report issued on Wednesday, MarketBeat reports. They currently have a $85.00 target price on the medical device company’s stock. Rothschild & Co Redburn’s price objective points to a potential upside of 5.99% from the stock’s current price.

COO has been the topic of several other reports. Robert W. Baird raised their target price on Cooper Companies from $85.00 to $98.00 and gave the company an “outperform” rating in a research report on Friday, December 5th. Needham & Company LLC decreased their price target on Cooper Companies from $100.00 to $99.00 and set a “buy” rating for the company in a research note on Tuesday, February 3rd. Weiss Ratings upgraded shares of Cooper Companies from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, January 12th. The Goldman Sachs Group reaffirmed a “sell” rating and issued a $73.00 price objective on shares of Cooper Companies in a report on Friday, January 9th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $94.00 target price (up from $83.00) on shares of Cooper Companies in a research report on Friday, December 5th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $90.36.

Cooper Companies Stock Down 2.2%

COO stock opened at $80.20 on Wednesday. The company has a quick ratio of 1.13, a current ratio of 1.89 and a debt-to-equity ratio of 0.30. Cooper Companies has a fifty-two week low of $61.78 and a fifty-two week high of $91.59. The firm’s 50-day simple moving average is $82.23 and its 200 day simple moving average is $75.95. The stock has a market cap of $15.65 billion, a PE ratio of 42.66, a price-to-earnings-growth ratio of 2.34 and a beta of 1.02.

Cooper Companies (NASDAQ:COO) last posted its earnings results on Thursday, March 5th. The medical device company reported $1.10 EPS for the quarter, topping the consensus estimate of $1.03 by $0.07. Cooper Companies had a net margin of 9.16% and a return on equity of 10.02%. The firm had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.02 billion. During the same quarter in the prior year, the firm earned $0.92 EPS. Cooper Companies’s quarterly revenue was up 6.2% on a year-over-year basis. Cooper Companies has set its Q2 2026 guidance at 4.580-4.660 EPS. As a group, sell-side analysts predict that Cooper Companies will post 3.98 EPS for the current year.

Insider Buying and Selling at Cooper Companies

In other news, Director Cynthia L. Lucchese bought 1,784 shares of the stock in a transaction that occurred on Monday, December 22nd. The shares were purchased at an average cost of $84.06 per share, with a total value of $149,963.04. Following the completion of the acquisition, the director directly owned 9,445 shares in the company, valued at approximately $793,946.70. The trade was a 23.29% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Albert G. White III purchased 10,000 shares of the business’s stock in a transaction on Tuesday, December 16th. The stock was acquired at an average cost of $80.80 per share, with a total value of $808,000.00. Following the completion of the acquisition, the chief executive officer directly owned 236,151 shares in the company, valued at $19,081,000.80. The trade was a 4.42% increase in their position. The SEC filing for this purchase provides additional information. Over the last three months, insiders have purchased 16,014 shares of company stock valued at $1,304,416. Corporate insiders own 2.08% of the company’s stock.

Institutional Trading of Cooper Companies

A number of large investors have recently added to or reduced their stakes in COO. Vanguard Group Inc. increased its holdings in shares of Cooper Companies by 1.8% in the second quarter. Vanguard Group Inc. now owns 24,254,677 shares of the medical device company’s stock valued at $1,725,963,000 after buying an additional 421,423 shares in the last quarter. Capital World Investors raised its position in shares of Cooper Companies by 25.7% during the third quarter. Capital World Investors now owns 10,551,592 shares of the medical device company’s stock worth $723,417,000 after purchasing an additional 2,159,233 shares during the period. State Street Corp lifted its holdings in shares of Cooper Companies by 2.4% during the fourth quarter. State Street Corp now owns 8,793,747 shares of the medical device company’s stock valued at $720,736,000 after purchasing an additional 207,195 shares during the last quarter. Wellington Management Group LLP boosted its position in shares of Cooper Companies by 332.9% in the 3rd quarter. Wellington Management Group LLP now owns 6,184,992 shares of the medical device company’s stock valued at $424,043,000 after purchasing an additional 4,756,178 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its stake in Cooper Companies by 58.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,028,821 shares of the medical device company’s stock worth $494,123,000 after purchasing an additional 2,231,568 shares in the last quarter. 24.39% of the stock is currently owned by institutional investors.

Key Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Q1 EPS beat and raised guidance — Cooper reported $1.10 EPS, topping consensus and issued firmer forward guidance that management framed as confidence in the business, which initially drove an intraday rally. Cooper Companies stock jumps 4% on earnings beat, raised guidance
• Positive Sentiment: Solid underlying profitability and cash flow — company disclosures and third‑party summaries show improving margins, higher operating profit and stronger operating cash flow year-over-year, supporting longer‑term earnings durability. The Cooper Companies (COO) Stock Falls on Q1 2026 Earnings
• Neutral Sentiment: Strategic review highlighted — company commentary and coverage note a strategic review is in focus; this can signal potential portfolio moves (M&A, divestitures or capital returns) but is undetermined in timing and outcome. Cooper Companies earnings up next: Strategic review in focus
• Neutral Sentiment: Company release and investor materials available — the press release, slides and call recording give details on segment trends and guidance assumptions for investors who want to dig into backlog, regional mix and product momentum. CooperCompanies Announces First Quarter 2026 Results
• Neutral Sentiment: Analyst and media summaries provide metric context — coverage from Zacks and SFGate summarizes how revenue, EPS and margins compared to estimates and last year, useful for model adjustments but not decisively bullish or bearish. The Cooper Companies (COO) Reports Q1 Earnings: What Key Metrics Have to Say
• Negative Sentiment: Analyst downgrade and mixed sell‑side views — Rothschild & Co Redburn downgraded COO to neutral with an $85 target; analysts remain split with price targets ranging widely, increasing near‑term volatility risk. Finviz (Rothschild & Co Redburn downgrade note)
• Negative Sentiment: Market reaction / headline confusion — some outlets report the stock fell after the print despite positives, reflecting investor focus on mixed revenue/estimate comparisons, messy guidance wording in headlines, and profit‑taking after an initial jump. The Cooper Companies (COO) Stock Falls on Q1 2026 Earnings

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.